Obálka

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodation...

Celý popis

Uloženo v:
Hlavní autor: Martínez-Cordero, Humberto (author)
Další autoři: Peña, Camila (author), Schutz, Natalia Paola (author), Bove, Virginia (author), Villano, Fiorella (author), Beltrán, Cecilia (author), Donoso, Javiera (author), López-Vidal, Hernán (author), Roa Salinas, Macarena Alejandra (author), Soto, Pablo (author), Ochoa, Paola (author), Duarte, Patricio (author), Riva, Eloísa (author)
Médium: article
Jazyk:angličtina
Vydáno: 2023
Témata:
PERSONA DE MEDIANA EDAD
PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA
BORTEZOMIB
CICLOFOSFAMIDA
DEXAMETASONA
MIELOMA MÚLTIPLE
PRONÓSTICO
TALIDOMIDA
RESULTADO DEL TRATAMIENTO
USOS TERAPÉUTICOS
QUIMIOTERAPIA
EPIDEMIOLOGÍA
On-line přístup:https://hdl.handle.net/20.500.12008/53300
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky: Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Podobné jednotky